Navigation Links
Spherix Reports Second Quarter 2009 Earnings

BETHESDA, Md., Aug. 17 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the second quarter ended June 30, 2009.

Recent and Upcoming Company Highlights

  • Biospherics Subsidiary
    • Clinical trials on Naturlose (D-tagatose) as a treatment for Type 2 diabetes:
      • Announced preliminary Phase 2 clinical trial data demonstrating reduction of HbA1c levels with doses of Naturlose an order of magnitude lower than the dose used in the current Phase 3 trial
      • Spherix anticipates having Phase 3 interim data results in third quarter of 2009
      • Completion of the Phase 2 Dose Range clinical trial expected in mid-2010
      • Completion of the Phase 3 clinical trial expected in mid- to late-2010
    • Received first production batch of cGMP (FDA Current Good Manufacturing Practice) D-tagatose, USP (U.S. Pharmacopeia) grade from Inalco S.p.A., of Italy
    • Upcoming trade shows/investor conferences:
      • Rodman & Renshaw 11(th) Annual Health Conference, New York, NY, Sept. 9-11
      • American Academy of Family Practice, Boston, MA, Oct. 14-17
      • BIO Investor Forum, San Francisco, CA, Oct. 28-30
  • Spherix Consulting Subsidiary
    • Upcoming professional and trade shows:
      • American College of Toxicology, 30(th) Annual Meeting, Palm Springs, CA, Nov. 1-4
      • Calorie Control Council, Ponte Vedra Beach, FL
      • Supply Side West, Las Vegas, NV, Nov. 11-13

"As announced on June 24, 2009, preliminary data from our Phase 2 dosing trial demonstrated statistically significant reductions in HbA1c levels at doses of Naturlose that are well below those being evaluated in the current Phase 3 trial," said Claire L. Kruger, CEO of Spherix. "We are excited by what these data suggest and the Company is pursuing steps to aggressively escalate our pharmaceutical marketing and commercialization plans for Naturlose. These plans include the formation of up to three regional Medical Advisory Boards, possibly as early as September 2009."

"Also in June, the Company received its first production batch of D-tagatose from Inalco S.p.A., a truly significant milestone on a number of levels. First, it shines a light on the full-scale cGMP process that will be used to produce Naturlose for use by patients in our Phase 3 clinical trial as well as for the anticipated commercialization of the drug. Second, as part of the Food and Drug Administration (FDA) approval process, a Drug Master File (DMF) has been submitted to the FDA and Spherix has a Letter of Authorization to refer to the DMF when it ultimately files its New Drug Application for Naturlose. Finally, receipt of this batch demonstrates Spherix's ability to use multiple sources to deliver the high volume of doses of Naturlose that would be needed to meet patient demands should we receive FDA approval."

"On a corporate level, I am happy to welcome Thomas B. Peter to the Company's Board. Mr. Peter's experience with GlaxoSmithKline and the commercialization of that company's Type 2 diabetes drug, Avandia, will be an invaluable addition to the vast expertise of the Company's Board members and officers."

Financial Results for the Quarter Ended June 30, 2009

Revenue was $332,000 for the quarter ended June 30, 2009, up from $263,000 in 2008 for the same period. Direct costs saw a corresponding increase to $109,000 from $99,000 between the same periods. The Company's revenue improvement reflects the growth of its health sciences consulting services ("Spherix Consulting").

Research and development expenses were $1.1 million in the quarter, up from $710,000 of the previous year. The increase in R&D expenses is related to the expansion of the Phase 3 trial to India. The Company's R&D expenses for both years consisted of costs for both the Phase 3 and Phase 2 clinical trials.

Selling, general and administrative expenses for the quarter were $649,000, down from $741,000 in the second quarter of 2008.

The net loss for the quarter ended June 30, 2009 was $1.6 million or $0.11 per share, compared with a net loss of $1.2 million or $0.08 per share for the same period in 2008.

Second-Quarter Conference Call

The Company will host a conference call tomorrow to discuss the results and business expectations. See instructions below to participate on the call.

Earnings Call: August 18, 2009 10:00 AM (Eastern Daylight Time)

Webcast Link:

Dial-in Information

Conference telephone number: 888-359-3610

Confirmation Code: 4748859

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

                               - Tables Follow -

                             Spherix Incorporated
                   Consolidated Statements of Operations
           For the Three and Six Months Ended June 30, 2009 and 2008

                        Three Months Ended June 30,  Six Months Ended June 30,
                        ---------------------------  -------------------------
                                2009         2008         2009         2008
                                ----         ----         ----         ----

    Revenue                   $332,241     $263,151     $692,911     $406,059
                           -----------  -----------  -----------  -----------

    Operating expense
      Direct costs             109,123       98,825      239,665      160,419
      Research and
       Development expense   1,133,962      709,941    2,695,351    1,741,149
      Selling, general and
        Expense                649,096      741,295    1,408,366    1,842,210
                           -----------  -----------  -----------  -----------
      Total operating
       Expense               1,892,181    1,550,061    4,343,382    3,743,778
                           -----------  -----------  -----------  -----------

    Loss from operations    (1,559,940)  (1,286,910)  (3,650,471)  (3,337,719)
      Interest income            5,400       88,637       29,847      225,212
                           -----------  -----------  -----------  -----------
    Loss before taxes       (1,554,540)  (1,198,273)  (3,620,624)  (3,112,507)

      Income tax expense             -            -            -            -
                           -----------  -----------  -----------  -----------

    Net loss               $(1,554,540) $(1,198,273) $(3,620,624) $(3,112,507)
                           ===========  ===========  ===========  ===========

    Net loss per share,
     basic                      $(0.11)      $(0.08)      $(0.25)      $(0.22)
    Net loss per share,
     diluted                    $(0.11)      $(0.08)      $(0.25)      $(0.22)

    Weighted average
     shares outstanding,
     basic                  14,357,162   14,318,702   14,357,162   14,318,702
                           ===========  ===========  ===========  ===========
    Weighted average
     shares outstanding,
     diluted                14,357,162   14,318,702   14,357,162   14,318,702
                           -----------  -----------  -----------  -----------

                          Spherix Incorporated
                      Consolidated Balance Sheets
             As of June 30, 2009 (unaudited) and December 31, 2008

    ASSETS                                June 30, 2009       December 31,
                                            (Unaudited)           2008
                                            -----------           ----
    Current assets
      Cash and cash equivalents              $6,392,955        $9,404,843
      Short-term investments                  1,599,346         1,894,434
      Trade accounts receivable                 339,356           281,342
      Other receivables                           6,142            37,223
      Prepaid expenses and other assets         174,979           282,971
                                            -----------       -----------

        Total current assets                  8,512,778        11,900,813

      Property and equipment, net               261,952           310,365
      Patents, net of accumulated
       amortization of $41,622 and $38,588       11,398            14,433
      Deposit                                    35,625            35,625
                                            -----------       -----------
        Total assets                         $8,821,753       $12,261,236
                                            ===========       ===========

    Current liabilities
      Accounts payable and accrued expenses    $982,697          $710,881
      Accrued salaries and benefits             230,524           304,756
      Deferred revenue                           96,316            39,347
                                            -----------       -----------
        Total current liabilities             1,309,537         1,054,984

      Deferred compensation                     585,000           660,000
      Deferred rent                             122,444           136,736
                                            -----------       -----------
        Total liabilities                     2,016,981         1,851,720
                                            -----------       -----------

    Commitments and contingencies                     -                 -

    Stockholders' equity
      Preferred stock, $0.01 par
       value, 2,000,000 shares authorized;
       none issued and outstanding                    -                 -
      Common stock, $0.005 par value,
       50,000,000 shares authorized;
       14,437,600 issued, and 14,357,162
       shares outstanding at June 30, 2009
       and December 31, 2008                     72,188            72,188
      Paid-in capital in excess of
       par value                             27,618,366        27,602,486
      Treasury stock, 80,438 shares, at
       cost at June 30, 2009 and
       December 31, 2008                       (464,786)         (464,786)
      Accumulated deficit                   (20,420,996)      (16,800,372)
                                            -----------       -----------
        Total stockholders' equity            6,804,772        10,409,516
                                            -----------       -----------
        Total liabilities and
         stockholders' equity                $8,821,753       $12,261,236
                                            -----------       -----------

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Termination of Arla License Agreement
2. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
3. Spherix Regains Full NASDAQ Compliance
4. Spherix to Exhibit at the BIO 2009 International Convention
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix Announces 2008 Financial Results
8. Spherix Reports 3rd Quarter Earnings
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
11. Spherix Receives NASDAQ Bid Price Deficiency Letter
Post Your Comments:
(Date:3/27/2017)...  Perthera,s Chief Bioinformatics Officer and research faculty member ... Ph.D., will be speaking at the American Medical Informatics ... 27, 2017, she will be speaking on the topic ... and Care" (from 10:30 a.m. – 12:00 p.m. PST) ... a participant in the "Making Precision Oncology Data More ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, Inc. ... therapies for neurodegenerative diseases, including Alzheimer,s disease, today ... application to list the Company,s common stock on ... The NASDAQ Stock Market, a unit of the ... will ring the Opening Bell at the NASDAQ ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Report" report to their offering. ... This report analyzes the Global market for ... and forecasts are provided for the period 2014 through 2022. Market ... The report profiles 25 companies including many key and ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
Breaking Biology News(10 mins):